AR131006A1 - Compuestos novedosos - Google Patents
Compuestos novedososInfo
- Publication number
- AR131006A1 AR131006A1 ARP230103005A ARP230103005A AR131006A1 AR 131006 A1 AR131006 A1 AR 131006A1 AR P230103005 A ARP230103005 A AR P230103005A AR P230103005 A ARP230103005 A AR P230103005A AR 131006 A1 AR131006 A1 AR 131006A1
- Authority
- AR
- Argentina
- Prior art keywords
- novel compounds
- compounds
- novel
- methods
- general formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La invención se refiere a compuestos novedosos que tienen la fórmula general (1) en donde R¹, R², R³, R⁴ᵃ, R⁴ᵇ y R⁵ son como se describe en la presente, composición que incluye los compuestos y métodos para usar los compuestos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP22206280 | 2022-11-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR131006A1 true AR131006A1 (es) | 2025-02-05 |
Family
ID=84330428
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP230103005A AR131006A1 (es) | 2022-11-09 | 2023-11-08 | Compuestos novedosos |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20260193228A1 (es) |
| EP (1) | EP4615830A1 (es) |
| JP (1) | JP2025537238A (es) |
| CN (1) | CN120152964A (es) |
| AR (1) | AR131006A1 (es) |
| TW (1) | TW202428282A (es) |
| WO (1) | WO2024099993A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11618751B1 (en) | 2022-03-25 | 2023-04-04 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives |
| US11319319B1 (en) | 2021-04-07 | 2022-05-03 | Ventus Therapeutics U.S., Inc. | Compounds for inhibiting NLRP3 and uses thereof |
| US12331048B2 (en) | 2022-10-31 | 2025-06-17 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors |
| CN121586712A (zh) * | 2023-07-28 | 2026-02-27 | 豪夫迈·罗氏有限公司 | 新颖化合物 |
| TW202545527A (zh) | 2024-01-16 | 2025-12-01 | 英商諾得瑟拉公司 | Nlrp3及glp-1a組合療法 |
| WO2025261430A1 (zh) * | 2024-06-21 | 2025-12-26 | 成都赜灵生物医药科技有限公司 | 苯并噻吩类氘代化合物及其用途 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR119731A1 (es) * | 2019-05-17 | 2022-01-05 | Novartis Ag | Inhibidores del inflamasoma nlrp3 |
| WO2021219784A1 (en) * | 2020-04-30 | 2021-11-04 | Janssen Pharmaceutica Nv | New triazinoindole compounds |
-
2023
- 2023-11-07 WO PCT/EP2023/080899 patent/WO2024099993A1/en not_active Ceased
- 2023-11-07 JP JP2025526484A patent/JP2025537238A/ja active Pending
- 2023-11-07 EP EP23801749.5A patent/EP4615830A1/en active Pending
- 2023-11-07 CN CN202380077209.5A patent/CN120152964A/zh active Pending
- 2023-11-07 US US19/128,439 patent/US20260193228A1/en active Pending
- 2023-11-08 TW TW112143032A patent/TW202428282A/zh unknown
- 2023-11-08 AR ARP230103005A patent/AR131006A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW202428282A (zh) | 2024-07-16 |
| US20260193228A1 (en) | 2026-07-09 |
| WO2024099993A1 (en) | 2024-05-16 |
| CN120152964A (zh) | 2025-06-13 |
| EP4615830A1 (en) | 2025-09-17 |
| JP2025537238A (ja) | 2025-11-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR130984A1 (es) | Compuestos novedosos | |
| AR123424A1 (es) | Nuevos compuestos heterocíclicos | |
| AR131282A1 (es) | Compuestos novedosos | |
| AR131278A1 (es) | Compuestos novedosos | |
| CL2021001330A1 (es) | Nuevos compuestos heterocíclicos | |
| CL2024004085A1 (es) | Compuestos macrocíclicos inhibidores de kras, uso para tratar cáncer. | |
| AR132377A1 (es) | Compuestos novedosos | |
| CO2023014721A2 (es) | Compuestos heterocíclicos | |
| CL2022001091A1 (es) | Dihidrobenzofurano e inden analogos como inhibidores de sarcómero cardíaco (divisional de solicitud 202001871). | |
| CL2023003312A1 (es) | Inhibidores de nlrp3 | |
| CL2022000019A1 (es) | Nuevos compuestos heterocíclicos | |
| AR132456A1 (es) | Compuestos novedosos | |
| CL2024001565A1 (es) | Compuestos macrocíclicos con actividad inhibidora de la farnesiltransferasa, composición que los comprende y su uso. | |
| AR133266A1 (es) | Macrociclos para el tratamiento de enfermedades autoinmunitarias | |
| MX2023015490A (es) | Inhibidores de las transglutaminasas. | |
| CR20240203A (es) | Compuestos de heteroaril-urea novedosos como inhibidores de kv7.2 | |
| AR132992A1 (es) | Agonistas de trem2 | |
| CL2025000484A1 (es) | Compuestos deuterados de pirimidin-2-il sulfonamida, uso para tratar trastornos desmielinizantes. | |
| CL2025000126A1 (es) | Compuestos derivados de indolsulfonamida y uso para tratar pérdida de mielina. | |
| CL2025000125A1 (es) | Compuestos derivados de indolsulfonamida y uso para tratar pérdida de mielina. | |
| CO2022012773A2 (es) | Moduladores de nampt | |
| AR133375A1 (es) | Compuestos novedosos | |
| AR133076A1 (es) | Compuestos novedosos | |
| AR133167A1 (es) | Macrociclos para el tratamiento de enfermedad autoinmunitaria | |
| AR131633A1 (es) | Derivados novedosos de pirimidinil sulfonamida |